. 2015 Sep 1;3(2):77–86. doi: 10.1093/nop/npv027

Table 2.

Randomized clinical evidence for elderly patients with glioblastoma

Title	Treatment Arm	Number of Patients	Age, Median (Range)	Outcome
Debulking or biopsy of malignant glioma in elderly people – a randomized study¹¹	Stereotactic biopsy Open craniotomy/ Resection	16 14	72 (67–79) 70 (66–80)	85 days (95% CI, 55–157) 171 days (95% CI, 146–278) (P = .035)
Radiotherapy for glioblastoma in the elderly¹⁸	Best supportive care Radiotherapy 50 Gy in 28 fractions with best supportive care	42 39	73 (70–85) 75 (70–84)	16.9 weeks (95% CI, 13.4–21.4) 29.1 weeks (95% CI, 25.4–34.9) HR for death in RT Group = 0.47 (95% CI, 0.29–0.76; P = .002 by the log-rank test)
Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial²¹	Standard radiotherapy (60 Gy in 2 Gy fractions over 6 weeks) Short-course regimen (40 Gy in 15 fractions over 3 weeks)	47 48	Mean 72.4 (SD 5.4) Mean 71 (SD 5.5)	Median survival 5.1 months Median survival 5.6 months (HR = 0.89; 95% CI, 0.59–1.36; P = .57)
Temozolomide chemotherapy alone vs radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 Randomised, phase 3 trial¹³	Temozolomide alone 100 mg/m² given on days 1–7 of 1 week every 14 days Radiotherapy 60 Gy, administered over 6-7 weeks in 30 fractions of 1.8–2.0 Gy	195 178	72 (66–84) 71 (66–82)	8.6 months (95% CI, 7.3–10.2) 9.6 months (95% CI, 8.2–10.8) (HR = 1.09, 95% CI, 0.84–1.42; P_{non inferiority} = .033)
Temozolomide vs standard 6-week radiotherapy vs hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial¹⁴	Standard radiotherapy (60 Gy in 2 Gy fractions over 6 weeks) Hypofractionated radiotherapy (34.0 Gy in 3·4 Gy fractions over 2 weeks Temozolomide (200 mg/m² on days 1–5 of every 28 days for up to 6 cycles)	100 98 93	70 years (60–80) 70 (60–83) 70 (60–88)	6.0 months (95% CI, 5.1–6.8) 7.5 months (95% CI, 6.5–8.6) 8.3 months (95% CI, 7.1–9.5)